innerbuddies gut microbiome testing

Gut Microbiome and Crohn’s Disease: How Inflammation Is Linked to Your Microbiota

Crohn’s disease is a chronic, inflammatory condition where the immune system can overreact to signals in the gut. Increasing evidence shows that this inflammation doesn’t happen in isolation—it's closely tied to the gut microbiome, the vast community of bacteria, viruses, and fungi living in your intestines. When the microbial ecosystem shifts, the balance between “helpful” and potentially harmful microbes can change, influencing how the gut lining responds to everyday triggers.

In many people with Crohn’s, researchers observe lower microbial diversity and patterns consistent with dysbiosis (an imbalance in the microbiome). These changes may affect digestion, mucus production, and the gut barrier’s integrity—making it easier for immune cells to sense bacterial components that normally wouldn’t cause trouble. Over time, that heightened immune sensing can amplify inflammation, contributing to symptoms and flare-ups.

Latest research suggests the relationship is bidirectional: not only can microbiome changes promote inflammatory pathways, but Crohn’s-related inflammation can further reshape the microbiome. Understanding which microbial shifts are linked to disease activity—and how diet, medications, and therapies may restore microbial balance—offers a path toward more targeted prevention and treatment strategies.

Buy Your Gut Microbiome Test for Crohn’s Get Your Gut Microbiome Test for Crohn’s
innerbuddies gut microbiome testing

Quick Summary

Crohn’s disease

Crohn's disease is a chronic relapsing inflammatory bowel condition in which immune dysregulation is closely linked to the gut microbiome. Dysbiosis can weaken the intestinal barrier and shift immune signaling, creating a cycle where inflammation and microbial imbalance reinforce each other. Microbiome-targeted approaches—dietary modulation, selective antibiotics or biologics that indirectly reshape communities, and strategies to restore microbial diversity (probiotics, prebiotics, and fecal microbiota–related therapies under study)—are being explored to support remission and reduce flares, with effectiveness varying by individual disease features and therapies.

Microbial patterns in Crohn's typically show reduced diversity and lower levels of anti-inflammatory, short-chain fatty acid–producing taxa, with concurrent increases in pro-inflammatory microbes. Functionally, loss of butyrate production and altered carbohydrate fermentation and bile acid metabolism can impair barrier integrity and promote inflammatory signaling through pathways such as Toll-like and NOD-like receptors. The inflammation–microbiome feedback loop is influenced by local environmental changes (oxygen, pH, bile acids), which further shape microbial communities and disease location/severity, correlating with symptoms like diarrhea and abdominal pain.

Testing the microbiome can help identify dysbiosis and functional deficits beyond the presence of specific microbes, guiding personalized interventions and monitoring response to diet, probiotics, and other microbiome-influencing strategies alongside standard Crohn's therapies. InnerBuddies offers a personalized microbiome snapshot to assess dysbiosis and protective functions, track shifts toward remission, and tailor dietary or probiotic plans, with repeat testing used to optimize management over time.

Buy Your Gut Microbiome Test for Crohn’s Get Your Gut Microbiome Test for Crohn’s
innerbuddies gut microbiome testing

Key takeaways

  1. Loss of butyrate-producing taxa (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Ruminococcus spp., Clostridium clusters XIVa/IV) reduces short-chain fatty acid production and weakens epithelial barrier function, fueling inflammation.
  2. Depletion of mucosal-protective taxa such as Akkermansia muciniphila, Bifidobacterium spp., and Bacteroides uniformis/fragilis diminishes mucus–epithelium maintenance and anti-inflammatory signaling, increasing permeability.
  3. Expansion of pro-inflammatory or adherent-invasive taxa (Escherichia coli/AIEC, Ruminococcus gnavus, Fusobacterium spp., Klebsiella spp., Bacteroides vulgatus) drives mucosal inflammation and barrier disruption.
  4. Dysbiosis alters pattern-recognition signaling (TLR/NOD-like receptors) through changed microbial antigens and metabolites, amplifying inflammatory cytokine responses.
  5. Shifts in the microbiome perturb bile acid metabolism and signaling, affecting immune regulation and potentially promoting inflammation.
  6. Active inflammation creates a gut environment that selects for more inflammatory taxa (Enterococcus spp., Streptococcus spp., Sutterella spp.), reinforcing dysbiosis and disease activity.
innerbuddies gut microbiome testing

Condition Overview

Inflammatory bowel disease (IBD) - Crohn’s disease

Crohn’s disease is a chronic, relapsing inflammatory bowel disease in which the immune system overreacts to triggers in the gut. One key driver of this dysregulated immune response is the gut microbiome—the diverse community of bacteria, viruses, fungi, and their metabolites that normally help maintain the intestinal lining and train immune tolerance. In many people with Crohn’s, shifts in microbial balance (often called dysbiosis) are associated with increased inflammation, changes in barrier function, and altered production of beneficial compounds such as short-chain fatty acids.

Research suggests that inflammation and microbiome changes can reinforce each other in a cycle. When the intestinal barrier becomes less effective, more microbial components can contact immune cells, promoting inflammatory signaling. At the same time, dysbiosis may reduce “protective” microbial functions (including those that produce anti-inflammatory metabolites) while increasing microbes or microbial byproducts that favor inflammatory pathways. This immune–microbe interplay can influence disease location and severity by affecting how immune cells recognize and respond to microbial antigens, contributing to persistent gut inflammation.

Current evidence also highlights potential prevention and treatment angles tied to the microbiome, though results vary and depend on individual disease features and therapies. Interventions such as diet-based microbiome modulation, targeted antibiotics or biologics that reshape microbial communities indirectly, and approaches aimed at restoring microbial diversity (e.g., probiotics, prebiotics, and fecal microbiota–related strategies under study) may help support remission or reduce flares for some patients. Ongoing studies are identifying specific microbial patterns and metabolites that correlate with risk, response to treatment, and inflammation—moving toward more personalized, microbiome-informed care for Crohn’s disease.

Buy Your Gut Microbiome Test for Crohn’s Get Your Gut Microbiome Test for Crohn’s
innerbuddies gut microbiome testing

Common Symptoms

  • Chronic diarrhea
  • Abdominal pain and cramping
  • Blood or mucus in the stool
  • Weight loss and reduced appetite
  • Fatigue
  • Fever
  • Perianal pain, swelling, or fistulas
innerbuddies gut microbiome testing

Who is it relevant for?

This information is most relevant for people living with Crohn’s disease (or suspected Crohn’s) who are experiencing ongoing or relapsing gut symptoms such as chronic diarrhea, abdominal pain/cramping, blood or mucus in the stool, weight loss, fatigue, or fever. If your disease flares seem unpredictable or you notice that symptoms persist despite standard therapies, microbiome-focused insights may help explain why inflammation in the gut can continue—and why changes in the intestinal environment may be part of the process.

It is also relevant for patients with Crohn’s disease where the gut barrier appears compromised, since barrier dysfunction can allow more microbial components to interact with immune cells and amplify inflammatory signaling. This is especially important for those who experience significant GI inflammation, persistent symptoms, or complications such as perianal pain, swelling, or fistulas, where immune–microbe interplay may contribute to disease severity and recurrence.

Finally, this content is helpful for anyone interested in microbiome-informed prevention or treatment options—particularly individuals seeking complementary approaches alongside their gastroenterology care. If you’re considering diet-based microbiome modulation, targeted medication strategies that can indirectly reshape the microbiome, or therapies related to restoring microbial balance (such as probiotics, prebiotics, or fecal microbiota–related approaches under study), this overview can guide understanding of how dysbiosis and protective microbial functions (including short-chain fatty acid production) may influence flare risk and response to treatment.

innerbuddies gut microbiome testing

Prevalence Summary

Crohn’s disease is a relatively uncommon but important inflammatory bowel disease, typically affecting millions of people worldwide. In most epidemiologic studies, the overall prevalence is often estimated at roughly 0.3%–0.4% of the population (about 3–4 per 1,000 people), with wide variation by region, genetics, and environmental exposures. Incidence rates are also lower than ulcerative colitis but remain substantial, commonly on the order of ~6–10 new cases per 100,000 people per year in many high-income countries.

In terms of demographic patterns, Crohn’s disease can occur at any age but is frequently diagnosed in younger adults (and there is a meaningful pediatric/teen subset), contributing to long-term disease burden. Population-based data also suggest that men and women are affected at similar rates overall, though age of onset can shift by region. The chronic, relapsing nature of Crohn’s—reflected in symptoms such as chronic diarrhea, abdominal pain/cramping, blood or mucus in stool, weight loss, fatigue, fever, and sometimes perianal pain, swelling, or fistulas—means that prevalence remains relatively stable over time once individuals are diagnosed, even when annual incidence is lower.

Crohn’s disease prevalence is influenced by differences in diagnostic practices and by environmental factors that may also interact with the gut microbiome (e.g., sanitation, diet patterns, antibiotic exposure, and smoking). Because symptoms can vary by disease location and severity—ranging from mild intermittent flares to complications such as strictures or fistulas—some cases may be diagnosed later, potentially affecting measured prevalence. Nonetheless, across multiple cohorts and meta-analyses, Crohn’s consistently remains a diagnosis affecting a small fraction of the population (commonly a few per 1,000), with meaningful global impact given its tendency toward chronic inflammation and relapse.

innerbuddies gut microbiome testing

Gut Microbiome and Crohn’s Disease: How Inflammation Is Linked to Your Microbiota

Crohn’s disease is closely connected to the gut microbiome because immune dysregulation in the intestine often follows changes in the microbial community (dysbiosis). Normally, a balanced microbiome helps maintain the intestinal barrier, supports immune tolerance, and produces metabolites that calm inflammation. In many people with Crohn’s, shifts in microbial composition and function are associated with impaired barrier integrity and altered immune recognition of gut microbes, which can promote ongoing inflammatory signaling.

Research suggests a reinforcing cycle between inflammation and microbiome disruption in Crohn’s. When the gut barrier becomes less effective, microbial components and metabolites more easily reach immune cells in the gut wall, triggering inflammatory pathways. At the same time, dysbiosis can reduce “protective” microbial functions—such as the production of short-chain fatty acids and other anti-inflammatory metabolites—while increasing microbes or byproducts that favor inflammation. This immune–microbe feedback loop may influence where disease occurs, how severe it becomes, and why symptoms such as chronic diarrhea, abdominal pain, and bleeding can persist or flare.

Because the microbiome may help drive both inflammation and symptom activity, microbiome-informed approaches are being explored to support remission and reduce flares. Strategies under study include diet-based interventions that reshape microbial ecology, targeted antibiotics that can alter microbial populations indirectly, and biologic therapies that may change the microbiome by dampening inflammation. Treatments aiming to restore microbial diversity—such as probiotics and prebiotics in selected cases, and fecal microbiota–related approaches where appropriate—are promising but vary depending on individual disease characteristics and current therapies. These efforts also align with emerging research identifying specific microbial patterns and metabolites linked to inflammation, response to treatment, and risk.

Buy Your Gut Microbiome Test for Crohn’s Get Your Gut Microbiome Test for Crohn’s
innerbuddies gut microbiome testing

Mechanisms Involved

  • Dysbiosis-driven loss of intestinal barrier integrity: altered microbial composition and metabolites can weaken tight junctions, increase gut permeability, and allow luminal microbes/components to access the gut wall and trigger inflammation.
  • Immune dysregulation and abnormal microbial recognition: changes in microbial antigens and pattern-recognition signals (e.g., altered Toll-like receptor/NOD-like receptor pathways) can break immune tolerance and promote persistent activation of inflammatory T cell responses.
  • Reduced anti-inflammatory metabolite production (e.g., short-chain fatty acids): loss of microbes that produce butyrate/SCFAs may impair epithelial energy supply, mucus maintenance, and anti-inflammatory signaling (including regulatory immune pathways).
  • Increased pro-inflammatory microbial signals: enrichment of certain taxa or microbial byproducts (such as inflammatory lipopolysaccharide-like molecules or other immunostimulatory components) can amplify cytokine production and inflammatory cascades.
  • Reinforcing inflammation–microbiome feedback loop: ongoing intestinal inflammation alters the gut environment (pH, oxygen availability, bile acids, nutrient flow), which further shifts the microbiome toward a dysbiotic, inflammation-promoting state.
  • Altered bile acid metabolism and signaling: dysbiosis can change bile acid pools and their conversion to signaling forms that modulate host inflammation through bile acid receptors (e.g., FXR/TGR5).
  • Microbiome-mediated effects on disease distribution and complications: site-specific microbial ecology and metabolite gradients may influence lesion location (e.g., small bowel vs colon), severity, and risk of stricturing or fistulizing disease.
innerbuddies gut microbiome testing

Mechanism Explainer

Crohn’s disease is strongly influenced by the gut microbiome because immune regulation in the intestinal lining is tightly linked to the composition and activity of resident microbes. In a healthy state, a balanced microbiome supports barrier integrity, helps maintain immune tolerance to gut antigens, and produces metabolites that dampen excessive inflammation. In Crohn’s, dysbiosis—changes in microbial communities and their functions—can weaken the intestinal barrier (through effects on tight junctions and gut permeability), allowing microbial products and metabolites to reach immune cells in the gut wall more easily and trigger ongoing inflammatory signaling.

Beyond barrier disruption, dysbiosis can drive immune dysregulation by altering how the immune system recognizes microbial patterns. When the types and amounts of microbial antigens and pattern-recognition signals shift (including pathways such as Toll-like and NOD-like receptor signaling), tolerance may break down and inflammatory T cell responses can persist. At the same time, beneficial organisms that normally generate anti-inflammatory metabolites—especially short-chain fatty acids like butyrate—may be reduced, impairing epithelial energy supply, mucus maintenance, and regulatory immune pathways. This combination of loss of protective functions and gain of immunostimulatory signals can amplify cytokine production and perpetuate tissue inflammation.

Importantly, Crohn’s inflammation and the microbiome can reinforce each other in a feedback loop. Active inflammation alters the intestinal environment (such as oxygen levels, pH, bile acid processing, and nutrient availability), which further reshapes the microbiome toward a dysbiotic, inflammation-promoting state. Changes in bile acid pools and their signaling through bile-acid receptors can also modulate host immune responses. Over time, microbiome-driven differences in local metabolites and microbial ecology may help influence disease location and severity, affecting symptoms like diarrhea and bleeding and contributing to complications such as stricturing or fistulizing disease.

innerbuddies gut microbiome testing

Microbial Patterns Summary

In Crohn’s disease, microbial patterns often reflect reduced diversity and a shift away from commensal, barrier-supporting organisms toward communities enriched for taxa associated with inflammation. Across studies, authors frequently report depletion of beneficial groups linked to anti-inflammatory metabolite production (especially short-chain fatty acids such as butyrate) and expansion of microbes whose metabolic activities can favor pro-inflammatory signaling. Functionally, this shows up as altered pathways for carbohydrate fermentation, mucus interaction, and bile acid metabolism—processes that normally help maintain epithelial integrity and immune tolerance.

A common feature of Crohn’s-associated dysbiosis is disrupted ecological balance at the mucosal interface, where changes in the relative abundance and activity of resident microbes may drive abnormal immune recognition. When the microbial “signal” landscape changes—through shifts in microbial antigens and pathogen-associated molecular patterns—pattern-recognition pathways (for example, Toll-like and NOD-like receptor signaling) can become more inflammatory, promoting persistent activation of effector T cells and pro-inflammatory cytokines. At the same time, loss of organisms that generate regulatory metabolites and support tight junction function can increase gut permeability, making it easier for bacterial products to access immune cells in the gut wall.

Crohn’s microbial patterns also tend to show a reinforcement loop between inflammation and community remodeling. Active disease can create a gut environment with altered oxygen exposure, pH, bile acid composition, and nutrient availability, which collectively select for microbiome states that are more inflammation-promoting and less protective. This includes changes in bile acid pools and their signaling through bile-acid receptors, which can further skew immune responses and perpetuate dysbiosis. As a result, microbiome and metabolite profiles may correlate with disease location and severity and track with symptom flares such as chronic diarrhea, abdominal pain, and bleeding.

innerbuddies gut microbiome testing

Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Ruminococcus spp.
  • Akkermansia muciniphila
  • Bifidobacterium spp.
  • Bacteroides uniformis / Bacteroides fragilis group
  • Clostridium clusters XIVa and IV (butyrate-producing consortia)
innerbuddies gut microbiome testing

Elevated / overrepresented taxa

  • Escherichia coli (adherent-invasive E. coli, AIEC strains)
  • Enterococcus spp.
  • Streptococcus spp.
  • Klebsiella pneumoniae / Klebsiella spp.
  • Ruminococcus gnavus
  • Fusobacterium spp.
  • Sutterella spp.
  • Bacteroides vulgatus
innerbuddies gut microbiome testing

Functional pathways involved

  • Short-chain fatty acid (butyrate) synthesis and butyrate-dependent epithelial barrier support (loss of SCFA-producing consortia)
  • Mucus degradation and mucin utilization (altered interactions at the mucosal interface contributing to barrier dysfunction)
  • Carbohydrate fermentation pathways (shift away from protective fermentation toward pro-inflammatory metabolic outputs)
  • Bile acid metabolism and bile-acid signaling (modulation of FXR/TGR5-mediated immune and antimicrobial effects)
  • Pattern-recognition receptor signaling via microbial ligands (TLR/NOD/NLR signaling leading to pro-inflammatory cytokine production)
  • Inflammation-associated microbial antigen/pattern exposure and immune activation (antigen presentation and Th1/Th17 skewing)
  • Oxidative stress and oxygen/nutrient redox remodeling at the inflamed mucosa (supporting dysbiotic, inflammation-promoting communities)
innerbuddies gut microbiome testing

Diversity note

In Crohn’s disease, the gut microbiome often shows reduced diversity and a shift away from commensal, barrier-supporting communities. Compared with healthier microbiomes, many Crohn’s-associated profiles have fewer of the organisms that help maintain the intestinal lining and produce protective metabolites, especially short-chain fatty acids like butyrate. This loss of “beneficial” functional capacity can weaken the mucosal barrier, making it easier for microbial products to interact with immune cells in the gut wall.

As diversity declines, the remaining community is more likely to become imbalanced toward taxa and metabolic activities linked to inflammation. Functional changes frequently include altered carbohydrate fermentation, changes in how microbes interact with mucus, and disruptions in bile acid metabolism—processes that normally support epithelial integrity and immune tolerance. At the same time, the altered microbial “signal landscape” can increase immune activation, since pattern-recognition pathways may be stimulated by a different set of microbial antigens and byproducts.

A key feature of Crohn’s is that microbiome disruption and inflammation can reinforce each other, further narrowing diversity over time. In active disease, shifts in the intestinal environment—such as oxygen exposure, pH, nutrient availability, and bile acid composition—can select for microbiome states that are less protective and more pro-inflammatory. These ecological changes may track with disease location and severity and can fluctuate alongside symptom activity, contributing to ongoing or recurring flare patterns.


Why generic solutions fail

  • Issue with generic solutions

    In Crohn’s disease, “one-size-fits-all” gut interventions often fail because the drivers of inflammation are highly individualized and depend on the patient’s specific microbial ecology, disease location (ileal vs colonic vs perianal), and the degree of barrier dysfunction at the mucosal interface. Generic approaches that aim to broadly “improve gut health” may not restore the particular community structure and functional outputs (for example, short-chain fatty acid production such as butyrate, mucus support, and epithelial-tight-junction–friendly metabolites) that are missing in that person. When the protective metabolic functions aren’t targeted to the underlying dysbiosis pattern, the intervention can have minimal impact on immune tolerance and may not break the inflammation–microbe reinforcement loop.

    Another common reason generic solutions underperform is that Crohn’s dysbiosis is partly a consequence of the inflammatory milieu itself. Active inflammation changes oxygen exposure, pH, bile acid pools, and nutrient availability, which then selects for microbial states that are more inflammation-promoting. If a generic diet, supplement, or broad-spectrum probiotic regimen is introduced without accounting for these disease-context constraints—and without considering concurrent medications and baseline microbiome characteristics—it may not shift the ecosystem toward protective functions. In some cases, simply adding organisms or fermentable substrates without matching them to the patient’s current inflammatory activity and microbial deficits can even worsen symptoms for certain individuals.

    Finally, Crohn’s often involves immune dysregulation that is shaped by microbial antigens and microbial metabolites interacting with innate immune pathways (such as Toll-like and NOD-like signaling). Because different patients show different microbial “signal” landscapes, generic strategies may not modulate the specific immune recognition events driving their disease. Treatments that don’t account for microbial function (not just microbial presence), the metabolic chemistry of the gut (especially bile acid signaling and carbohydrate/mucus fermentation balance), and timing relative to flare status are therefore less likely to produce consistent remission or durable reductions in diarrhea, pain, and bleeding.

  • Common mistakes

    • Using one-size-fits-all probiotics or prebiotics without matching the patient’s specific Crohn’s microbial deficits (e.g., reduced SCFA/butyrate production, loss of mucus/epithelial-supporting taxa) and functional outputs.
    • Assuming “more fermentation” is always beneficial—adding broad fermentable fibers without accounting for active flare status can worsen symptoms (gas, diarrhea) when barrier function and oxygen/pH conditions favor pro-inflammatory fermentation patterns.
    • Ignoring disease location (ileal vs colonic vs perianal) and related ecology—failing to tailor bile-acid and carbohydrate/mucus interactions to where the dysbiosis is driving inflammation.
    • Overlooking the inflammation-driven nature of dysbiosis—introducing generic interventions during high inflammatory activity can fail because the altered gut chemistry (oxygen exposure, bile acid pools, pH, nutrient availability) continues to select for inflammation-promoting communities.
    • Targeting microbial presence rather than microbial function—supplementing taxa without aiming for restoration of protective metabolic pathways (butyrate/SCFA generation, mucus interaction, tight-junction–friendly metabolites).
    • Not accounting for medication effects (e.g., corticosteroids, immunomodulators, biologics, antibiotics) that can profoundly change microbiome composition and the response to diet or supplements.
    • Neglecting inter-individual variation in microbial “signal” landscapes (microbial antigens/PAMPs that drive Toll-like/NOD-like and other innate immune signaling), leading to immune effects that generic products don’t reliably modulate.
    • Failing to consider barrier status and gut permeability—using broad gut-healing claims without addressing drivers that increase translocation of bacterial products that sustain immune activation.

What to do

  • General support strategies

    Crohn’s disease is strongly influenced by the gut microbiome: when dysbiosis disrupts immune balance and weakens the intestinal barrier, inflammatory signaling can become self-sustaining. A common goal of microbiome-informed support is to promote a healthier microbial ecosystem that supports barrier integrity, improves immune tolerance, and encourages production of metabolites with anti-inflammatory effects (such as short-chain fatty acids). In practice, this often means focusing on dietary patterns that help reshape microbial communities toward a more diverse, resilient state and reduce factors that may worsen gut inflammation in the individual.

    Research also supports the idea of breaking the inflammation–microbe feedback loop by modulating microbial composition and function. Diet-based interventions can be tailored to promote beneficial microbes and reduce gut irritation during flares, while targeted approaches that alter microbial populations—under clinician guidance—may be considered when appropriate. In parallel, core Crohn’s therapies (including biologics) help control immune activation; by dampening inflammation, they can indirectly influence the microbiome, making it easier for protective microbial functions to recover.

    Additional supportive strategies being explored include probiotics and prebiotics in selected cases, aiming to improve microbial balance and metabolic output, as well as fecal microbiota–related approaches where clinically appropriate. Because responses vary based on disease location, severity, current medications, and baseline microbiome patterns, the most effective strategy is usually individualized—aligning gut-focused nutritional support and microbiome modulation with standard Crohn’s disease management to help maintain remission and reduce flare risk.

  • Lifestyle recommendations

    • Eat a gut-friendly, anti-inflammatory diet tailored to your tolerance (often Mediterranean-style), emphasizing fiber from tolerable sources and limiting foods that reliably worsen symptoms.
    • Consider a structured approach to diet trials (e.g., temporary low-FODMAP or specific carbohydrate–type strategies) with clinician/dietitian guidance, especially during flares or if you have strictures/active symptoms.
    • Reduce gut irritation by minimizing ultra-processed foods, added sugars, and alcohol; avoid or limit foods that increase diarrhea or pain based on your symptom pattern.
    • Prioritize smoking cessation (and avoid nicotine products), since smoking is strongly associated with more severe Crohn’s and higher relapse risk.
    • Support remission with adequate hydration and nutrition, and avoid skipping meals; if weight loss or deficiencies occur, ask for nutrient monitoring (iron, B12, vitamin D) and targeted supplementation.
    • Manage stress with evidence-based techniques (e.g., CBT, mindfulness, exercise within tolerance, breathing/relaxation), since stress can worsen symptom perception and flares in some people.
    • Use antibiotics and anti-diarrheal meds only as directed and discuss any microbiome-targeting options (probiotics/prebiotics) with your gastroenterologist, particularly if you are on biologics or have severe disease.

  • Nutrition recommendations

    • Use an individualized, anti-inflammatory “Crohn’s-friendly” diet (often Mediterranean-style) emphasizing omega-3 fats (fatty fish or chia/flax), olive oil, nuts (if tolerated), fruits/vegetables you digest well, and lean proteins; limit ultra-processed foods that may worsen dysbiosis.
    • Prioritize gut-tolerated fiber: during flares choose low-fiber options (e.g., peeled/cooked vegetables) and gradually increase soluble fiber (oats, psyllium, well-cooked carrots/zucchini) in remission to support beneficial SCFA production.
    • Support the microbiome with prebiotic foods when tolerated (e.g., oats, bananas/plantains, legumes in smaller portions, chicory root/inulin only if symptoms allow) and avoid aggressive fiber escalation that can trigger bloating/diarrhea.
    • Consider a structured carbohydrate approach if symptoms are sensitive to fermentation: some people benefit from limiting high-FODMAP foods during symptom flares while maintaining overall nutrition adequacy.
    • If you develop vitamin/mineral deficiencies (common in Crohn’s), focus on nutrient-dense sources and supplementation as advised—especially vitamin D, vitamin B12, iron, folate, calcium, and zinc.
    • Stay well-hydrated and manage diarrhea with nutrition strategies: adequate fluids/electrolytes; choose binding, low-irritant foods during flares (e.g., rice, bananas, oatmeal), and monitor caffeine/alcohol if they worsen symptoms.
    • For active disease or significant malnutrition risk, discuss medical nutrition therapy such as exclusive or partial enteral nutrition with your clinician/dietitian (an evidence-based option in Crohn’s for inducing remission).

  • Supplement considerations

    For Crohn’s disease, supplement considerations often focus on supporting a resilient gut barrier and encouraging an anti-inflammatory microbiome balance, since dysbiosis and immune dysregulation commonly reinforce each other. When the intestinal lining is less effective, microbial components and metabolites can interact more strongly with immune cells in the gut wall, sustaining inflammatory signaling. Supplements that can promote microbial metabolic “normalization”—for example by increasing beneficial fermentation products like short-chain fatty acids—may be relevant, but they should be chosen with attention to symptom pattern, current diet, and the specific inflammatory features of the disease.

    In practice, prebiotics and targeted fibers are frequently considered to support beneficial microbes, though tolerance varies widely in Crohn’s because added fermentable substrates can worsen bloating or diarrhea in some people. Probiotics may help in selected patients by shifting microbial composition and strengthening mucosal immune regulation, but responses are strain- and dose-dependent, and not all probiotic products are supported for Crohn’s in the same way. Because Crohn’s is heterogeneous, it’s also important to consider the potential interactions with ongoing therapy; for instance, biologics and immunomodulators may change the inflammatory environment in a way that influences how well a microbiome-targeted supplement works.

    Safety and practicality are also key considerations. People with Crohn’s who are immunocompromised, have strictures, or experience severe active flares may need to avoid or carefully tailor supplements that increase stool bulk or fermentation. It can be useful to coordinate supplementation with a clinician, especially when considering high-dose or multi-strain probiotic regimens, gut-active antimicrobials, or anything marketed for “microbiome resets.” Ultimately, the goal is to select evidence-informed options that support remission maintenance and reduce flare risk, rather than expecting one supplement to fully correct the complex inflammation–microbiome feedback loop that drives Crohn’s.

  • Retesting / monitoring note

    For Crohn’s disease, retesting is typically considered when there is a meaningful change in symptoms, after starting or adjusting a therapy, or when results are needed to guide next-step decisions. Because Crohn’s is linked to gut microbiome dysbiosis and immune–barrier dysfunction, it can be helpful to re-evaluate the microbiome (and related inflammatory signals) to see whether microbial diversity, function, and metabolite patterns are moving toward a more remission-associated profile. Retesting may also be recommended if prior testing was performed during an active flare, since acute inflammation, diet changes, antibiotics, and bowel preparation can temporarily shift microbial composition and make comparisons harder.

    In practice, many clinicians time retesting to match expected biological “settling” after treatment changes. For microbiome-related assays, retesting is often scheduled after a washout period from antibiotics (and sometimes after steroids or biologics are stabilized, depending on the specific test and clinical goals). If fecal biomarkers or inflammatory markers are part of the testing strategy, the timing is generally aligned with when inflammation is expected to stabilize—commonly over several weeks rather than days. Consistency matters: collecting samples the same way each time (same stool type/location when applicable, same collection kit, and prompt storage/transport) improves the reliability of trend comparisons.

    Finally, retesting should be framed around clinical intent rather than repeating tests automatically. It’s most useful when it can answer a question—such as whether a diet-based microbiome intervention (e.g., fiber-targeted approaches), a probiotic or prebiotic strategy, or a change in Crohn’s medication is associated with improved microbial function and reduced inflammatory signatures. If the goal is to reduce flare risk or personalize nutrition and therapy, retesting intervals may be set to monitor directionality over time, especially when there’s ongoing symptoms (diarrhea, abdominal pain, bleeding) or concerns about treatment response. Your care team should interpret results in context with endoscopy, stool markers, and clinical course to determine whether another round of interventions is warranted.

The importance of gut microbiome testing

  • Why testing matters

    In Crohn’s disease, the intestinal microbiome can influence both immune behavior and barrier function, so the “who is there and what they’re doing” question is clinically relevant. Gut microbiome testing can help identify patterns of dysbiosis—such as loss of beneficial, anti-inflammatory microbial functions or enrichment of microbes associated with inflammatory signaling—that may correlate with active disease, symptom flares, and ongoing intestinal damage. By capturing functional readouts (not just species), testing may provide insight into whether protective metabolites (like short-chain fatty acids) are reduced and whether microbial byproducts that can promote inflammation are more prominent.

    Microbiome testing may also matter because Crohn’s often involves a feedback loop between inflammation and microbial disruption. When inflammation weakens the mucosal barrier, microbial components can interact more readily with immune cells in the gut wall, sustaining inflammatory pathways; meanwhile dysbiosis can further impair immune tolerance. Testing can therefore support a more personalized understanding of disease biology—helping clinicians and patients track whether interventions are shifting the microbiome toward a composition and metabolic profile associated with remission, rather than relying solely on symptoms that may lag behind biological change.

    Finally, results from gut microbiome testing can inform how diet, probiotics/prebiotics, and other microbiome-influencing strategies are chosen and monitored alongside standard Crohn’s therapies. Because Crohn’s varies widely in location, severity, and treatment response, microbiome-informed approaches may be tailored to an individual’s baseline microbial ecology and resilience. In the context of biologics and other therapies, testing can also help set realistic expectations by identifying whether the microbiome is recovering in the way linked to improved tolerance and reduced inflammatory signaling—turning microbiome testing into a tool for both optimization and follow-through.

  • How InnerBuddies helps

    InnerBuddies can help provide a personalized snapshot of the gut microbiome in Crohn’s disease by looking at patterns that reflect dysbiosis—changes in which microbes are present and how the community may be behaving functionally. Because Crohn’s involves immune dysregulation and often impaired intestinal barrier function, shifts in the microbiome can influence inflammatory signaling, symptom activity, and the overall intestinal environment. By identifying microbiome patterns linked in research to inflammation or to reduced protective activity, InnerBuddies may help translate the biology behind Crohn’s into information that’s easier to act on clinically and nutritionally.

    In Crohn’s, there is often a reinforcing loop where inflammation disrupts the gut barrier and microbial balance, and dysbiosis further supports ongoing immune activation. InnerBuddies testing may support this “feedback loop” understanding by showing whether the microbiome looks more aligned with active inflammation versus remission-associated profiles. It can also help highlight whether protective, anti-inflammatory microbial functions (for example, those related to gut metabolites such as short-chain fatty acids) appear diminished, and whether community features that may correlate with inflammatory processes seem more prominent.

    By using microbiome-informed insights, InnerBuddies can help guide and monitor microbiome-supporting strategies alongside standard Crohn’s management—such as diet changes designed to reshape microbial ecology, and selected probiotic or prebiotic approaches when appropriate. Instead of relying on symptoms alone (which may lag behind biological change), repeat testing can be used to check whether the microbiome is shifting toward a composition and metabolic direction associated with improved tolerance and reduced inflammatory potential, helping patients and clinicians optimize interventions over time.

Medical Evidence

  • Scientific evidence level

    2 [weak—emerging but inconsistent for clinical relevance; stronger for biological plausibility than for causality or actionability]

  • Clinical relevance note

    Current clinical relevance is limited. Although multiple studies show that CD is associated with gut microbiome alterations, the field does not yet have a validated, reproducible microbiome signature (stool- or mucosa-based) that can reliably distinguish CD status, predict individual prognosis, or guide therapy with clinically meaningful accuracy. The strongest “actionable” takeaway today is conceptual: microbiome dysfunction may contribute to intestinal inflammation and could become a target, but current evidence does not justify routine microbiome testing or microbiome-based treatment decisions for CD outside research settings.

    Interventions that modulate the microbiome (probiotics, prebiotics, diet, antibiotics, FMT/synbiotics) have not demonstrated consistent, durable benefits across well-powered trials with standardized endpoints, and they are confounded by concomitant medications and baseline disease heterogeneity. Additionally, stool microbiome may not accurately reflect the mucosal microbiome where inflammation is localized in CD, further weakening translational confidence. In practice, clinical decision-making still relies on established diagnostic criteria, endoscopy/imaging, biomarkers (e.g., CRP/fecal calprotectin), and therapeutics guided by phenotype and standard-of-care evidence rather than microbiome profiling.


Below is a list of the most important medical publications linked to this specific condition.

Title Journal Year Link
Fecal microbiota transplantation is effective for recurrent Clostridioides difficile infection but its role in inflammatory bowel disease remains uncertain: a systematic review. Nature Reviews Gastroenterology & Hepatology 2019 —
Role of gut microbiota in the pathogenesis of Crohn’s disease. Gastroenterology 2015 —
Association of gut microbiota with treatment response in Crohn’s disease. Gastroenterology 2014 —
A reference map of the human gut microbiome enables personalized nutrition and health. Nature 2014 —
Reduced diversity and altered composition of the gut microbiome in Crohn’s disease. Nature Medicine 2011 —

Frequently Asked Questions

    What is Crohn's disease and how does it affect the gut?
    Crohn's disease is a chronic inflammatory bowel condition. It can cause ongoing gut inflammation, diarrhea, abdominal pain, and sometimes complications like fistulas or strictures.
    How is the gut microbiome involved in Crohn's disease?
    The microbiome is a community of microbes in the gut. In Crohn's, imbalances (dysbiosis) and altered microbial functions can interact with the immune system and the gut barrier to influence inflammation.
    What is dysbiosis and why does it matter in Crohn's?
    Dysbiosis means an imbalance in gut microbes. In Crohn's, it is often linked to reduced protective metabolites and more inflammatory signals, which may contribute to symptoms and flares.
    What symptoms are common with Crohn's disease?
    Chronic diarrhea, abdominal pain/cramps, blood or mucus in stool, weight loss, fatigue, fever, and sometimes perianal pain or fistulas.
    How common is Crohn's disease?
    It is relatively uncommon but affects millions worldwide. Prevalence is about 0.3–0.4% (roughly 3–4 per 1,000 people); incidence is typically 6–10 new cases per 100,000 people per year in many high-income countries.
    How can microbiome testing help in Crohn's disease?
    Testing aims to identify dysbiosis patterns and functional changes that may relate to inflammation and symptom activity, potentially guiding diet or other microbiome-related strategies. It is not a substitute for standard care.
    What is the difference between testing microbiome composition vs. function?
    Composition testing looks at which microbes are present; functional testing looks at what they are doing (metabolic activity). Both provide different, useful insights.
    What does InnerBuddies offer in Crohn's disease?
    InnerBuddies provides a microbiome snapshot focusing on dysbiosis patterns and related functions to support discussions with your clinician about diet or other strategies. It is not a diagnosis.
    Are there dietary or lifestyle strategies to support the microbiome in Crohn's?
    Diet- and lifestyle approaches that modulate the microbiome are being studied; results vary. Discuss with your clinician what might be appropriate for you.
    Are probiotics, prebiotics, or fecal microbiota therapies useful in Crohn's?
    Probiotic/prebiotic and fecal microbiota–related approaches are under study. They may help some people but are not universal cures and depend on individual factors.
    How do inflammation and the microbiome influence each other in Crohn's?
    Inflammation can alter the gut environment, shaping the microbiome; dysbiosis can promote inflammatory signals, creating a feedback loop that sustains disease activity.
    What does the evidence say about microbiome–informed care?
    Research suggests potential for personalized care using microbiome data, but results vary. Microbiome information should complement, not replace, standard treatments.
    What should I ask my doctor about microbiome testing?
    Ask whether microbiome testing is appropriate for you, how results could influence management, costs, timelines, and how to interpret changes over time.

    Gut Microbiome and Crohn’s disease

    →

    Gut Microbiome and Small intestinal bacterial overgrowth (SIBO)

    →

    Gut Microbiome and Gut-liver axis

    →

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -